Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2008 Oct 1;5(4):583–591. doi: 10.1016/j.nurt.2008.08.013

Approaching a new age in Duchenne muscular dystrophy treatment

Kathryn R Wagner 1,2,✉
PMCID: PMC4514703  PMID: 19019310

Summary

Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy. The cornerstones of current treatment include corticosteroids for skeletal muscle weakness, afterload reduction for cardiomyopathy, and noninvasive ventilation for respiratory failure. With these interventions, patients are walking and living longer. However, the current status is still far from adequate. Increased private and federal funding of studies in Duchenne muscular dystrophy has led to a large number of novel agents with propitious therapeutic potential. These include agents that modify dystrophin expression, increase muscle growth and regeneration, and modulate inflammatory responses. Many of these agents are already in clinical trials. Challenges to the development of additional novel therapeutics exist, including lack of validated animal models and lack of adequate biomarkers as surrogate endpoints. However, these challenges are not insurmountable and the next decade will likely see meaningful, new treatment options introduced into the clinical care of patients with Duchenne muscular dystrophy.

Key Words: Duchenne, muscular dystrophy, clinical trials, therapeutics, myostatin, gene therapy

References

  • 1.Moxley RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. 2005;64:13–20. doi: 10.1212/01.WNL.0000148485.00049.B7. [DOI] [PubMed] [Google Scholar]
  • 2.Fitch K, Bernstein SJ, Aguilar MS, et al. The RAND/UCLA Appropriateness Method User’s Manual. Santa Monica, CA: RAND Corp; 2001. [Google Scholar]
  • 3.Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991;48:383–388. doi: 10.1001/archneur.1991.00530160047012. [DOI] [PubMed] [Google Scholar]
  • 4.Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. New Engl J Med. 1989;320:1592–1597. doi: 10.1056/NEJM198906153202405. [DOI] [PubMed] [Google Scholar]
  • 5.Manzur AY, Kukntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Review). The Cochrane Library 2006:1–41.
  • 6.Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. J Bone Joint Surg Am. 2004;86-A:519–524. doi: 10.2106/00004623-200403000-00009. [DOI] [PubMed] [Google Scholar]
  • 7.Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromusc Disord. 2006;16:249–255. doi: 10.1016/j.nmd.2006.01.010. [DOI] [PubMed] [Google Scholar]
  • 8.King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68:1607–1613. doi: 10.1212/01.wnl.0000260974.41514.83. [DOI] [PubMed] [Google Scholar]
  • 9.Pandya S, Guntrum D, Moxley RT. Long term daily prednisone therapy delays decline in pulmonary function and improves survival in patients with Duchenne dystrophy. Neuromusc Disord. 2005;15:687–687. [Google Scholar]
  • 10.Wagner KR, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta. 2007;1772:229–237. doi: 10.1016/j.bbadis.2006.06.009. [DOI] [PubMed] [Google Scholar]
  • 11.Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromusc Disord. 2002;12:912–925. doi: 10.1016/s0960-8966(02)00180-3. [DOI] [PubMed] [Google Scholar]
  • 12.Fenichel GM, Mendell JR, Moxley RT, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 1991;48:575–579. doi: 10.1001/archneur.1991.00530180027012. [DOI] [PubMed] [Google Scholar]
  • 13.Kinali M, Mercuri E, Main M, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromusc Disord. 2002;12(suppl 1):S169–S174. doi: 10.1016/S0960-8966(02)00097-4. [DOI] [PubMed] [Google Scholar]
  • 14.Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve. 1994;17:386–391. doi: 10.1002/mus.880170405. [DOI] [PubMed] [Google Scholar]
  • 15.Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138:45–50. doi: 10.1067/mpd.2001.109601. [DOI] [PubMed] [Google Scholar]
  • 16.Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23:1344–1347. doi: 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 17.Eagle M, Baudouin S, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromusc Disord. 2002;12:926–929. doi: 10.1016/S0960-8966(02)00140-2. [DOI] [PubMed] [Google Scholar]
  • 18.Mohr CH, Hill NS. Long-term follow-up of nocturnal ventilatory assistance in patients with respiratory failure due to Duchenne-type muscular dystrophy. Chest. 1990;97:91–96. doi: 10.1378/chest.97.1.91. [DOI] [PubMed] [Google Scholar]
  • 19.Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax. 1998;53:949–952. doi: 10.1136/thx.53.11.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005;84:843–850. doi: 10.1097/01.phm.0000184156.98671.d0. [DOI] [PubMed] [Google Scholar]
  • 21.Daftary AS, Crisanti M, Kalra M, et al. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics. 2007;119:e320–e324. doi: 10.1542/peds.2006-1400. [DOI] [PubMed] [Google Scholar]
  • 22.Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990;26:271–277. doi: 10.1016/0167-5273(90)90082-G. [DOI] [PubMed] [Google Scholar]
  • 23.Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromusc Disord. 2008;18:365–370. doi: 10.1016/j.nmd.2008.03.002. [DOI] [PubMed] [Google Scholar]
  • 24.Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45:855–857. doi: 10.1016/j.jacc.2004.09.078. [DOI] [PubMed] [Google Scholar]
  • 25.Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. New Engl J Med 1987;316:1429–1435. [DOI] [PubMed]
  • 26.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New Engl J Med 1991;325:293–302. [DOI] [PubMed]
  • 27.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13. [PubMed]
  • 28.Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587. doi: 10.1016/S0140-6736(00)02213-3. [DOI] [PubMed] [Google Scholar]
  • 29.Segal B, Pitt R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet. 1997;349:747–752. doi: 10.1016/S0140-6736(97)01187-2. [DOI] [PubMed] [Google Scholar]
  • 30.Griggs RC, Moxley RTr, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology. 1993;43:520–527. doi: 10.1212/WNL.43.3_Part_1.520. [DOI] [PubMed] [Google Scholar]
  • 31.Kissel JT, Lynn DJ, Rammohan KW, et al. Mononuclear cell analysis of muscle biopsies in prednisone and azathrioprine treated Duchenne muscular dystrophy. Neurology. 1993;43:532–536. doi: 10.1212/WNL.43.3_Part_1.532. [DOI] [PubMed] [Google Scholar]
  • 32.Fisher I, Abraham D, Bouri K, et al. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J. 2005;19:834–836. doi: 10.1096/fj.04-2511fje. [DOI] [PubMed] [Google Scholar]
  • 33.Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the duchenne muscular dystrophy locus. Cell. 1987;51:919–928. doi: 10.1016/0092-8674(87)90579-4. [DOI] [PubMed] [Google Scholar]
  • 34.Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: Successes, limitations and recent advances. Biochim Biophys Acta. 2007;1772:243–262. doi: 10.1016/j.bbadis.2006.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Rando TA. Non-viral gene therapy for Duchenne muscular dystrophy: progress and challenges. Biochim Biophys Acta. 2007;1772:263–271. doi: 10.1016/j.bbadis.2006.07.009. [DOI] [PubMed] [Google Scholar]
  • 36.Crawford GE, Faulkner JA, Crosbie RH, et al. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol. 2000;150:1399–1410. doi: 10.1083/jcb.150.6.1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Fabb SA, Wells DJ, Serpente P, Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micodystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet. 2002;11:733–741. doi: 10.1093/hmg/11.7.733. [DOI] [PubMed] [Google Scholar]
  • 38.Liu M, Yue Y, Harper SQ, et al. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther. 2005;11:245–256. doi: 10.1016/j.ymthe.2004.09.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Sakamoto M, Yuasa K, Yoshimura M, et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun. 2002;293:1265–1272. doi: 10.1016/S0006-291X(02)00362-5. [DOI] [PubMed] [Google Scholar]
  • 40.Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A. 2000;95:10158–10163. doi: 10.1073/pnas.240335297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Duan D, Yan Z, Engelhardt JF. Expanding the capacity of AAV vectors. London, New York: Hodder Arnold; 2006. pp. 525–532. [Google Scholar]
  • 42.Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther. 2007;16:124–130. doi: 10.1038/sj.mt.6300322. [DOI] [PubMed] [Google Scholar]
  • 43.Salva MZ, Himeda CL, Tai PWL, et al. Design of tissue-specific regulatory cassettes for high-level raav-mediated expression in skeletal and cardiac muscle. Mol Ther. 2007;15:320–329. doi: 10.1038/sj.mt.6300027. [DOI] [PubMed] [Google Scholar]
  • 44.Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, et al. Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther. 2004;10:232–240. doi: 10.1016/j.ymthe.2004.05.031. [DOI] [PubMed] [Google Scholar]
  • 45.Denti MA, Rosa A, D’Antona G, et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci U S A. 2006;103:3758–3763. doi: 10.1073/pnas.0508917103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A. 2005;102:198–203. doi: 10.1073/pnas.0406700102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New Engl J Med. 2007;357:2677–2686. doi: 10.1056/NEJMoa073108. [DOI] [PubMed] [Google Scholar]
  • 48.Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999;104:375–381. doi: 10.1172/JCI7866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Dunant P, Walter MC, Karpati G, Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve. 2003;27:624–627. doi: 10.1002/mus.10341. [DOI] [PubMed] [Google Scholar]
  • 50.Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker Muscular Dystrophy due to nonsense mutations. Ann Neurol. 2001;49:706–711. doi: 10.1002/ana.1023. [DOI] [PubMed] [Google Scholar]
  • 51.Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91. doi: 10.1038/nature05756. [DOI] [PubMed] [Google Scholar]
  • 52.Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007;47:430–444. doi: 10.1177/0091270006297140. [DOI] [PubMed] [Google Scholar]
  • 53.Engert JC, Berglund EB, Rosenthal N. Proliferation precedes differentiation in IGF-1 stimulated myogenesis. J Cell Biol. 1996;135:431–440. doi: 10.1083/jcb.135.2.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Rosenthal SM, Cheng ZQ. Opposing early and late effects of insulin-like growth factor 1 on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci U S A. 1995;92:10307–10311. doi: 10.1073/pnas.92.22.10307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell B. 2005;37:1974–1984. doi: 10.1016/j.biocel.2005.04.018. [DOI] [PubMed] [Google Scholar]
  • 56.Barton ER, Morris L, Musaro A, et al. Muscle-specific expression of insulin-like growth factor 1 counters muscle decline in mdx mice. J Cell Biol. 2002;157:137–147. doi: 10.1083/jcb.200108071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Shavlakadze T, White J, Hoh JFY, et al. Targeted expression of insulin-like growth factor-1 reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther. 2004;10:829–843. doi: 10.1016/j.ymthe.2004.07.026. [DOI] [PubMed] [Google Scholar]
  • 58.Gregorevic P, Plant DR, Leeding KR, et al. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-1 administration. Am J Pathology. 2002;161:2263–2271. doi: 10.1016/S0002-9440(10)64502-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83–90. doi: 10.1038/387083a0. [DOI] [PubMed] [Google Scholar]
  • 60.Lee S-J. Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet. 2007;23:475–477. doi: 10.1016/j.tig.2007.08.008. [DOI] [PubMed] [Google Scholar]
  • 61.Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. New Engl J Med. 2004;350:2682–2688. doi: 10.1056/NEJMoa040933. [DOI] [PubMed] [Google Scholar]
  • 62.Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol. 2002;52:832–836. doi: 10.1002/ana.10385. [DOI] [PubMed] [Google Scholar]
  • 63.McCroskery S, Thomas M, Platt L, et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci. 2005;118:3531–3541. doi: 10.1242/jcs.02482. [DOI] [PubMed] [Google Scholar]
  • 64.Wagner KR, Liu X, Chang X, Allen RE. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci U S A. 2005;102:2519–2524. doi: 10.1073/pnas.0408729102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.McCroskery S, Thomas M, Maxwell L, et al. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol. 2003;162:1135–1147. doi: 10.1083/jcb.200207056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Rios R, Carneiro I, Arce VM, Devesa J. Myostatin is an inhibitor of myogenic differentiation. Am J Physiol Cell Physiol. 2002;282:C993–999. doi: 10.1152/ajpcell.00372.2001. [DOI] [PubMed] [Google Scholar]
  • 67.Taylor WE, Bhasin S, Artaza J, et al. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab. 2001;280:E221–228. doi: 10.1152/ajpendo.2001.280.2.E221. [DOI] [PubMed] [Google Scholar]
  • 68.Thomas M, Langley B, Berry C, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem. 2000;275:40235–40243. doi: 10.1074/jbc.M004356200. [DOI] [PubMed] [Google Scholar]
  • 69.Wagner KR. Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol. 2005;17:720–724. doi: 10.1097/01.bor.0000184163.61558.ca. [DOI] [PubMed] [Google Scholar]
  • 70.Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem 2008:M802585200. [DOI] [PMC free article] [PubMed]
  • 71.Zhu J, Li Y, Shen W, et al. Relationship between TGF-beta1, myostatin and decorin: implications for skeletal muscle fibrosis. J Biol Chem. 2007;282:25852–25863. doi: 10.1074/jbc.M704146200. [DOI] [PubMed] [Google Scholar]
  • 72.Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 2004;20:61–86. doi: 10.1146/annurev.cellbio.20.012103.135836. [DOI] [PubMed] [Google Scholar]
  • 73.Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102:18117–18122. doi: 10.1073/pnas.0505996102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420:418–421. doi: 10.1038/nature01154. [DOI] [PubMed] [Google Scholar]
  • 75.Qiao C, Li J, Jiang J, et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther. 2008;19:241–254. doi: 10.1089/hum.2007.159. [DOI] [PubMed] [Google Scholar]
  • 76.Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561–571. doi: 10.1002/ana.21338. [DOI] [PubMed] [Google Scholar]
  • 77.Allen RE, Boxhorn LK. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J Cell Physiol. 1987;1987:576–572. doi: 10.1002/jcp.1041330319. [DOI] [PubMed] [Google Scholar]
  • 78.Li Y, Foster W, Deasy BM, et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathology. 2004;164:1007–1019. doi: 10.1016/S0002-9440(10)63188-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Olson EN, Sternberg E, Hu JS, et al. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol. 1986;103:1799–1805. doi: 10.1083/jcb.103.5.1799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-beta1 in dystrophic patient muscles correlates with fibrosis. J Clin Invest. 1995;96:1137–1144. doi: 10.1172/JCI118101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Chen YW, Nagaraju K, Bakay M, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 2005;65:826–834. doi: 10.1212/01.wnl.0000173836.09176.c4. [DOI] [PubMed] [Google Scholar]
  • 82.Zanotti S, Negri T, Cappelletti C, et al. Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain. 2005;128:2546–2555. doi: 10.1093/brain/awh635. [DOI] [PubMed] [Google Scholar]
  • 83.Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204–210. doi: 10.1038/nm1536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Lavoie P, Robitaille G, Agharazii M, et al. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertension. 2005;23:1895–1903. doi: 10.1097/01.hjh.0000182521.44440.c5. [DOI] [PubMed] [Google Scholar]
  • 85.Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789–791. doi: 10.1161/01.CIR.103.6.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Hayden MS, Ghosh S. Shared principles in NF-kB signaling. Cell. 2008;132:344–362. doi: 10.1016/j.cell.2008.01.020. [DOI] [PubMed] [Google Scholar]
  • 87.Mourkioti F, Rosenthal N. NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med. 2008;86:747–759. doi: 10.1007/s00109-008-0308-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Acharyya S, Villalta SA, Bakkar N, et al. Interplay of IKK/NK-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest. 2007;117:889–901. doi: 10.1172/JCI30556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Monici MC, Aguennouz M, Mazzeo A, et al. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology. 2003;60:993–997. doi: 10.1212/01.WNL.0000049913.27181.51. [DOI] [PubMed] [Google Scholar]
  • 90.Porter JD, Khanna S, Kaminski HJ, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002;11:263–272. doi: 10.1093/hmg/11.3.263. [DOI] [PubMed] [Google Scholar]
  • 91.Kuntz C, Tesi-Rocha N, Clemens PR, et al. Immediate release oral pentoxifylline is poorly tolerated in Duchenne muscular dystrophy boys. Neurology. 2008;70(suppl 1):A79–A79. [Google Scholar]
  • 92.Escolar D, Gorni K, Tesi-Rocha A, et al. Pentoxifylline treatment fails to rescue muscle strength and function deterioration in prednisone-treated Duchenne muscular dystrophy. Neurology. 2008;70(suppl 1):A79–A79. [Google Scholar]
  • 93.Burkin DJ, Wallace GQ, Nicol KJ, et al. Enhanced expression of the alpha7-beta1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol. 2001;152:1207–1218. doi: 10.1083/jcb.152.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Nguyen HH, Jayasinha V, Xia B, et al. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci U S A. 2002;99:5616–5621. doi: 10.1073/pnas.082613599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Hildebrand A, Romaris M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and firbomodulin with transforming growth factor beta. Biochem J. 1994;302:527–534. doi: 10.1042/bj3020527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Rafii MS, Hagiwara H, Mercado ML, et al. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol. 2006;209:439–447. doi: 10.1002/jcp.20740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Wiberg C, Hedbom E, Khairullina A, et al. Biglycan and deocrin bind close to the n-terminal region of the collagen VI triple helix. J Biol Chem. 2001;276:18947–18952. doi: 10.1074/jbc.M100625200. [DOI] [PubMed] [Google Scholar]
  • 98.Casar JC, McKechnie BA, Fallon JR, et al. Transient up-regulation of biglycan during skeletal muscle regeneration: delayed fiber growth along with decorin increase in biglycan-deficient mice. Dev Biol. 2004;268:358–371. doi: 10.1016/j.ydbio.2003.12.025. [DOI] [PubMed] [Google Scholar]
  • 99.Mercado ML, Amenta AR, Hagiwara H, et al. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J. 2006;20:1724–1726. doi: 10.1096/fj.05-5124fje. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984;81:1189–1192. doi: 10.1073/pnas.81.4.1189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Dubowitz V. Therapeutic efforts in Duchenne muscular dystrophy: the need for a common language between basic scientists and clinicians. Neuromusc Disord. 2004;14:451–455. doi: 10.1016/j.nmd.2004.06.002. [DOI] [PubMed] [Google Scholar]
  • 102.Sharp NJ, Kornegay JN, Van Camp SD, et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics. 1992;13:115–121. doi: 10.1016/0888-7543(92)90210-J. [DOI] [PubMed] [Google Scholar]
  • 103.Cooper BJ, Winand NJ, Stedman H, et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature. 1988;334:154–156. doi: 10.1038/334154a0. [DOI] [PubMed] [Google Scholar]
  • 104.Valentine BA, Winand NJ, Pradhan D, et al. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. Am J Med Genet. 1992;42:352–356. doi: 10.1002/ajmg.1320420320. [DOI] [PubMed] [Google Scholar]
  • 105.Wagner J. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol. 2008;48:631–651. doi: 10.1146/annurev.pharmtox.48.113006.094611. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES